Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04364789 · ClinicalTrials.gov registry record · Phase 1
Phase I, First-In-Human Study of TT-00920 in Healthy Subjects
A Phase 1 study, sponsored by TransThera Sciences (Nanjing).
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT04364789 is a Phase 1 study that has completed, run by TransThera Sciences (Nanjing). The registered enrollment target is 42 participants.
The verdict
NCT04364789, a Phase 1 study, has completed, sponsored by TransThera Sciences (Nanjing).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
This is a first-in-human, randomized, double-blind, placebo-controlled study. The primary objectives of the study were to investigate the safety and tolerability and determine the PK profiles of single ascending doses (SAD) of TT-00920 administered to healthy subjects. The secondary objectives of the study were to assess the effect of food on the PK of TT-00920 following an oral dose.
Interventions
- DRUG Placebos
- DRUG TT-00920
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2020-02-05 |
| Est. Completion | 2022-03-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04364789
The ClinicalTrials.gov registry entry for NCT04364789 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TransThera Sciences (Nanjing), which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebos is the first listed.
NCT04364789 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04364789 about?
NCT04364789 is a clinical study titled "Phase I, First-In-Human Study of TT-00920 in Healthy Subjects". This is a first-in-human, randomized, double-blind, placebo-controlled study. The primary objectives of the study were to investigate the safety and tolerability and determine the PK profiles of single ascending doses (SAD) of TT-00920 administered to healthy subjects. The secondary objectives of th...
What is the current status of trial NCT04364789?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2020-02-05. Estimated completion is 2022-03-17.
What interventions are being tested in trial NCT04364789?
The interventions under investigation include: Placebos (DRUG), TT-00920 (DRUG).
Who is sponsoring clinical trial NCT04364789?
This trial is sponsored by TransThera Sciences (Nanjing), which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.